CMS RBCS · Treatments · Injections and Infusions (nononcologic)

Injection - Immunomodulator codes

8 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Treatment J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 26.77M services · est. ▲ 5.8% YoY · 33,754 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 13.11M observed fee-for-service services

See the national market for J0129 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 1.94M services · est. ▲ 116.1% YoY · 41,814 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 937,303 observed fee-for-service services

See the national market for Q5128 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2778 Injection, ranibizumab, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.40M services · est. ▼ 53.8% YoY · 31,895 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 689,609 observed fee-for-service services

See the national market for J2778 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0256 Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 1.13M services · est. · 79 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 563,396 observed fee-for-service services

See the national market for J0256 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 697,567 services · est. ▼ 51.4% YoY · 2,013 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 355,143 observed fee-for-service services

See the national market for Q5119 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5124 Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 267,399 services · est. ▲ 9.8% YoY · 6,165 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 162,417 observed fee-for-service services

See the national market for Q5124 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 256,581 services · est. ▼ 37.8% YoY · 1,070 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 131,406 observed fee-for-service services

See the national market for Q5115 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2779 Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 6,616 services · est. ▼ 12.3% YoY · 26 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,300 observed fee-for-service services

See the national market for J2779 → ranked groups · states · 12-yr trend